Here are the DEF 14A proxy statements from Solventum Corporation (SOLV) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow SOLV and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SOLV filings page.
Solventum Corporation is asking shareholders to vote at its 2026 virtual annual meeting on May 15 on three items: electing four Class II directors, approving an advisory say‑on‑pay resolution, and ratifying PwC as independent auditor.
The proxy highlights Solventum’s first full year as a standalone MedTech company, with 2025 sales of $8.3B, diluted GAAP EPS of $8.88, diluted adjusted EPS of $6.11, reported sales growth of +0.9% and organic sales growth of +3.3%. MedSurg generated 58% of net sales, with Dental Solutions and Health Information Systems each at 16%.
Management underscores portfolio moves, including divesting the Purification & Filtration business to Thermo Fisher Scientific while retaining drinking water filtration, completing its first acquisition (Acera Surgical), and launching a share repurchase program. The Board emphasizes independent leadership with an independent Chair, majority voting for directors, phased declassification by 2028, and robust committee oversight of risk, strategy, talent, and science.
The compensation program is positioned as pay‑for‑performance, with 92% of CEO and 81% of other named executive officer target compensation at risk, heavily weighted to long‑term equity tied to multi‑year revenue, EPS and relative total shareholder return metrics. The Board reports broad 2025 shareholder outreach representing over 56% of outstanding shares (excluding 3M’s 14.7% stake) and cites adding relative TSR to performance share units in response to investor feedback.